Date: 2012-10-31
Type of information: Subvention
Company: Haemostatix (UK)
Investors: Wellcome Trust (UK)
Albion Ventures (UK)
Catapult Venture Managers (UK)
Spark Ventures (UK)
Esperante (UK)
Nesta (UK)
the Lachesis Fund
The University of Leicester (UK)
private share-holders (UK)
Amount: £1.4 million (€1.78 million) + £800,000
Funding type: award
Planned used: The new funds will enable Haemostatix to progress its lead product, PeproStat, into clinical trials. PeproStat is a new class of peptide-based haemostat that controls bleeding by binding to the blood protein, fibrinogen, to rapidly form a clot. Haemostats are used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery. Current haemostatic products may be limited by a slow onset of action as well as a lack of “ready-to-use” formulations. Additionally leading brands are based on an enzyme, thrombin, that is extracted from human donor blood. PeproStat has been designed to overcome these limitations, and the clinical trial will test the product’s safety and effectiveness in man.
Others: Haemostatix Ltd, a biopharmaceutical company, has received an additional £1.4 million Translation Award from the Wellcome Trust to continue development of its innovative haemostat technology. The funding coincides with a further £800,000 investment from Albion Ventures, Catapult Venture Managers, Spark Ventures, Esperante, Nesta, the Lachesis Fund, The University of Leicester and private share-holders.
Therapeutic area: Hemostasis
